Document Detail


Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
MedLine Citation:
PMID:  11693763     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The purpose of this study was to evaluate the effects of the angiotensin-converting enzyme (ACE) inhibitor imidapril and the calcium antagonist amlodipine on endothelial function before and after 2, 4, 8, 12, 24 and 48 weeks of treatment. BACKGROUND: There are limited data on whether and how long endothelial function is improved after initiation of ACE inhibitor treatment and how the grade of endothelial function further progresses after improvement of endothelial dysfunction in patients with essential hypertension. METHODS: The forearm blood flow (FBF) was measured in 25 patients with essential hypertension and in 25 normotensive subjects by using strain-gauge plethysmography during reactive hyperemia (RH) (280 mm Hg for 5 min) and after sublingual administration of nitroglycerin (NTG, 0.3 mg). RESULTS: The FBF of patients with essential hypertension during RH was significantly less than that of normotensive subjects. The increase in FBF after sublingual NTG was similar in both groups. Both imidapril (n = 13) and amlodipine (n = 12) significantly reduced systolic blood pressure and diastolic after eight weeks of treatment from the pretreatment values. Forearm vascular resistance was significantly decreased after two weeks of treatment. Imidapril significantly augmented RH after 12 weeks of treatment from the pretreatment values (31.6 +/- 5.7 to 38.2 +/- 6.0 m/min per 100 ml tissue, p < 0.05), whereas amlodipine did not alter RH for each treatment period. The ability of imidapril to improve RH was maintained throughout the 48-week treatment period. There was no significant difference in RH at 12, 24 and 48 weeks. The increase in FBF after sublingual administration of NTG was similar in all treatment periods for the two groups. The infusion of NG-monomethyl-L-arginine, a nitric oxide (NO) synthase inhibitor, abolished the enhancement of RH in hypertensive patients treated with imidapril. CONCLUSIONS: These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of treatment in patients with essential hypertension and that this ACE inhibitor-induced augmentation of RH may be due to an increase in NO.
Authors:
Y Higashi; S Sasaki; K Nakagawa; H Matsuura; G Kajiyama; T Oshima
Related Documents :
3894513 - Depressor effects of captopril in doca-salt hypertensive rats: role of vasopressin.
2175623 - Tissue angiotensin converting enzyme inhibition. relevant to clinical practice?
18419823 - Initial intramuscular perfusion pressure predicts early skeletal muscle function follow...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  37     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-11-05     Completed Date:  2001-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  863-70     Citation Subset:  AIM; IM    
Affiliation:
First Department of Internal Medicine , Hiroshima University School of Medicine, Japan. yhigashi@mcai.med.hiroshima-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Amlodipine / pharmacology
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Endothelium, Vascular / drug effects*,  physiopathology*
Female
Forearm / physiology
Humans
Hyperemia / physiopathology*
Hypertension / physiopathology*
Imidazoles / pharmacology*
Imidazolidines*
Male
Middle Aged
Regional Blood Flow / drug effects
Vascular Resistance / drug effects
Vasodilation / drug effects*
omega-N-Methylarginine / pharmacology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Imidazoles; 0/Imidazolidines; 17035-90-4/omega-N-Methylarginine; 88150-42-9/Amlodipine; 89396-94-1/imidapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary artery stenting in the aged.
Next Document:  Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts i...